Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Fig. 2

Comparison of survival outcomes between patients with different tumor diameters. a Overall survival (OS, months) in patients with a tumor diameter < 5 cm and those with a tumor diameter ≥ 5 cm. b Progression-free survival (PFS, months)in patients with a tumor diameter < 5 cm and those with a tumor diameter ≥ 5 cm. c Overall survival (OS, months) in patients with a tumor diameter < 7 cm and those with a tumor diameter ≥ 7 cm. d Progression-free survival (PFS, months)in patients with a tumor diameter < 7 cm and those with a tumor diameter ≥ 7 cm

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us